Emibetuzumab

Drug Profile

Emibetuzumab

Alternative Names: c-MET monoclonal antibody - Eli Lilly; cMET antibody - Eli Lilly; LA-480; LY-2875358

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer
  • Phase I/II Cancer

Most Recent Events

  • 26 Oct 2016 Eli Lilly and Company completes a phase I trial in Cancer (Late-stage disease, Combination therapy) in USA (NCT01287546)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Combination therapy) in Japan (IV)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top